Duopharma Biotech Bhd

Duopharma Biotech Bhd Interest Coverage

The Interest Coverage Ratio of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 3, 2026 is 5.08. In the previous year, Interest Coverage Ratio was 5.27 — a change of -3.62% (lower).

Interest Coverage

5.08

YoY

-3.62%

Last updated:

Interest Coverage Ratio of Duopharma Biotech Bhd is 2024 5.08 . Interest Coverage Ratio of Duopharma Biotech Bhd was 2023 5.27 . It decreases by -3.62% lower compared to the previous year.

The Duopharma Biotech Bhd Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
23.86 MYR
Jan 1, 2018
11.99 MYR
Jan 1, 2019
11.89 MYR
Jan 1, 2020
16.32 MYR
Jan 1, 2021
16.93 MYR
Jan 1, 2022
12.26 MYR
Jan 1, 2023
5.27 MYR
Jan 1, 2024
5.08 MYR
The Duopharma Biotech Bhd Interest Coverage history
YEARInterest CoverageYoY
5.08-3.62%
5.27-57.00%
12.26-27.58%
16.93+3.72%
16.32+37.31%
11.89-0.89%
11.99-49.73%
23.86-19.32%
29.57+38.83%
21.30-87.57%
171.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

Interest Coverage Ratio of Duopharma Biotech Bhd is 5.08 in 2024.

Interest Coverage Ratio of Duopharma Biotech Bhd changed from 5.27 to 5.08, representing a -3.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Duopharma Biotech Bhd with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd